CAMH will study PEX010, Filament’s botanical psilocybin drug candidate, in a Health Canada-approved clinical trial for mild cognitive impairment VANCOUVER, BC, Feb. 14, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical–stage natural psychedelic drug development company, today announced a second agreement to supply the Centre for…
Source